Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what ...

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Wisconsin is set to give Eli Lilly up to $100 million in Enterprise Zone tax credits for its $3 billion expansion in Bristol ...

Under the terms of the agreement, Eli Lilly is to make double-digit million-dollar upfront payments and invest in LTZ’s equity. In addition, LTZ is entitled to receive preclinical, clinical, ...